VTAK: catheterprecision.com EV/EBITDA Multiple

Catheter Precision (VTAK) delegates final assembly and parts molding to third-party contractors, which creates certain operational risks. This chart of EV/EBITDA dynamics, with a value of 0.00, complements the profile of this electrophysiology innovator that develops precision navigators to combat arrhythmia. The business relies on the defensive healthcare sector, where stable demand for cardiac mapping ensures revenue growth regardless of economic downturns.

Catheter Precision Corporation - VTAK Company Value to EBITDA (period 11/23/2025 - 10/05/2026)

VTAK (catheterprecision.com): analytical breakdowns and indicator data

- stock price and consensus target price:

Stock Quotes Catheter Precision Corp|VTAK - Analyst Forecast Prices

- market capitalization information:

Market Capitalization Catheter Precision Corporation|VTAK - Value Adjusted for Debt and Cash

- issuer book value statistics:

Book Value per Share Catheter Precision|VTAK - Total Stockholders' Equity|Market Cap to Net Assets Ratio catheterprecision.com|VTAK - Aggregate Business Assets

- debt and solvency information:

Total Debt to Capital Catheter Precision|VTAK - Long-Term Liabilities to Capital|Short-Term Debt to Equity Catheter Precision, Inc.|VTAK - Aggregate Debt Obligations|Debt to Book Value Catheter Precision Corporation|VTAK - Company Long-Term Loans and Borrowings|Company Short-Term Debt Catheter Precision|Quick Liquidity catheterprecision.com

- financial results and valuation multiples details:

VTAK - Final Profit|Projected Future Earnings Catheter Precision|VTAK - Market Cap to Earnings|Forward P/E Multiple Catheter Precision|VTAK - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Catheter Precision Corporation|VTAK - Operating income before deduction of amortization|Earnings per share for the last twelve months Catheter Precision|VTAK - Net earnings per share for the last four quarters|Quarterly EPS earnings growth catheterprecision.com|VTAK - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Catheter Precision

Summary company analysis:Catheter Precision Corp (VTAK)

Product sample of Catheter Precision, Inc.

For the high-tech sector of Catheter Precision (VTAK), business valuation through the lens of debt load is of critical importance. Analyzing the EV/EBITDA ratio in conjunction with capital structure allows for a comparison of the company's market value and its debt against actual operating profit before taxes. For this manufacturer of robotic ablation systems, this indicator separates the investment growth of the AI platform from over-leverage risks, signaling the fundamental stability of the asset.

Key competitors

Regeneron Inc. - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio IRTC (iRhythm Corp)|Lantheus Holdings, Inc. - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation MLYS (mineralystx.com)|HTFL: EV/EBITDA Multiple|Company Value to EBITDA Kestra Medical Technologies, Inc. (KMTS)|Enterprise Value to EBITDA Ratio ESPR|AMRN (Amarin Pharma) - Enterprise Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple AVR|TNYA - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CVRx CVRX|Business Value to Operating Income Before Depreciation MIST|CRDL: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation BEAT (HeartBeam Corporation)|Tenax Therapeutics (TENX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio ADGM (adagiomedical.com)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization BioCardia|ABIO: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ACST|AVTE - Company Value to EBITDA|EV/EBITDA Multiple VERV (Verve Therapeutics, Inc.)|WINT - Enterprise Value to EBITDA Ratio